Imke Beier - Concepedia

Author

Imke Beier

University Hospital Bonn

Also Known As

I Beier, I. Beier, IMKE BEIER, Imke Beier

Publications

455

Citations

H-Index

Concepts

All Affiliations

University Hospital Bonn University of Bonn

About

Imke Beier is an author at University Hospital Bonn specializing in cell biology, medicine, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	329
2	Cell Biology	5	5	329
3	Cellular Physiology	2	2	78
4	Immunology	2	2	168
5	Biochemistry	1	1	83

Imke Beier

Publications

426

Citations

H-Index

Page 1

	Year	Citations
Mechanism of Cytotoxicity Induced by Chimeric Mouse Human Monoclonal Antibody IDEC-C2B8 in CD20-Expressing Lymphoma Cell Lines Dimitri Flieger, Sabine Renoth, Imke Beier, Cellular Immunology Lymphoid NeoplasiaImmunologyCell DeathCytotoxicity InducedImmunophenotyping	2000	147
Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation Dominik Kraus, Jan Reckenbeil, Nadine Veit, Cellular Oncology Glucose TransportBiochemistryMedicineTumor CellsMetabolic Remodeling	2018	83
Angiotensin II-induced Stimulation of p21-activated Kinase and c-Jun NH2-terminal Kinase Is Mediated by Rac1 and Nck Udo K. Schmitz, Kerstin Thömmes, Imke Beier, Journal of Biological Chemistry	2001	63
Lysophosphatidic Acid Stimulates p21-Activated Kinase in Vascular Smooth Muscle Cells Udo K. Schmitz, Kerstin Thömmes, Imke Beier, Biochemical and Biophysical Research Communications Molecular PhysiologySignal TransductionMedicineVascular PharmacologyPhysiology	2002	51
Enhancement of Antibody Dependent Cellular Cytotoxicity (ADCC) by Combination of Cytokines Dimitri Flieger, Ulrich Spengler, Imke Beier, Hybridoma	1999	34
Epidermal growth factor stimulates Rac1 and p21-activated kinase in vascular smooth muscle cells Imke Beier, Rainer Düsing, H. Vetter, Atherosclerosis Epidermal Growth FactorMolecular PhysiologyAngiogenesisDevelopmental BiologySignal Transduction	2007	27
A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon α and interleukin-2 efficiently retargets T and CD3 + CD56 + natural-killer-like T lymphocytes to EpCAM-expressing tumor cells Dimitri Flieger, Peter Kufer, Imke Beier, Cancer Immunology Immunotherapy Cancer ImmunosurveillanceImmunologyTumor ImmunityImmunodominanceImmune Regulation	2000	21

Page 1